NCT05626634 2025-12-03
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 2 Completed
Longboard Pharmaceuticals
NYU Langone Health
Takeda
Beth Israel Deaconess Medical Center